TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20513595

Group type: EXPERIMENTAL
Intervention: Use of heparin + a glycoprotein IIb/IIIa inhibitor
Number of subjects: 17421

Group type: COMPARATOR
Intervention: Bivalirudin alone
Number of subjects: 17421

Group type: EXPERIMENTAL
Intervention: Major bleeding (non-CABG-related)
Number of subjects: 17421

Group type: EXPERIMENTAL
Intervention: Risk score based on 6 baseline measures plus anticoagulation regimen
Number of subjects: 17421
Study: 18062901

Group type: EXPERIMENTAL
Intervention: Levosimendan 0.1 microg/kg/min for 24 hours
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 15616225

Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (RT&WL group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control program (WL group)
Number of subjects: 36
Study: 12045757

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 5 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 10 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 15 mg
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 20 mg
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 9527752

Group type: EXPERIMENTAL
Intervention: Bromazepam (3 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clorazepate-dipotassium (20 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7614911

Group type: EXPERIMENTAL
Intervention: Aspartame (50 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2558705

Group type: EXPERIMENTAL
Intervention: Teflon-coated polyglycolic acid (Dexon plus)
Number of subjects: 1574

Group type: COMPARATOR
Intervention: Chromic catgut
Number of subjects: 1574

Group type: EXPERIMENTAL
Intervention: Polyglycolic acid
Number of subjects: 1574

Group type: COMPARATOR
Intervention: Silk
Number of subjects: 1574

Group type: EXPERIMENTAL
Intervention: Continuous subcuticular sutures
Number of subjects: 1574

Group type: COMPARATOR
Intervention: Interrupted transcutaneous sutures
Number of subjects: 1574
Study: 775990

Group type: EXPERIMENTAL
Intervention: Loridine-Keflex prophylaxis (antibiotics)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 30116989

Group type: EXPERIMENTAL
Intervention: Training program and counseling program
Number of subjects: 120
Study: 29275697

Group type: EXPERIMENTAL
Intervention: General functioning improvement treatments
Number of subjects: 118
Study: 26842502

Group type: EXPERIMENTAL
Intervention: 8-week physical activity intervention including shorter outdoor playtime (4 × 30 min), new portable play equipment, and staff training (1 × 4 hr workshop)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 8-week physical activity intervention
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study: 24549371

Group type: EXPERIMENTAL
Intervention: JNJ‐39758979 (H(4)R antagonist)
Number of subjects: 0
Study: 23032552

Group type: EXPERIMENTAL
Intervention: Mexiletine 200 mg orally 3 times daily for 4 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 19514441

Group type: EXPERIMENTAL
Intervention: Monitoring and correction of hemostatic disorders during intraoperative and postoperative periods
Number of subjects: 37
Study: 17055756

Group type: EXPERIMENTAL
Intervention: OMT+PTA
Number of subjects: 56

Group type: COMPARATOR
Intervention: OMT
Number of subjects: 56
Study: 16336830

Group type: EXPERIMENTAL
Intervention: Dopamine (DA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Norepinephrine (NE) combined with DA
Number of subjects: 30
Study: 11673584

Group type: EXPERIMENTAL
Intervention: Enlimomab
Number of subjects: 625

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 625
Study: 9389860

Group type: EXPERIMENTAL
Intervention: Rocuronium 1 ml (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.9% NaCl 1 ml (placebo)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rocuronium (second injection)
Number of subjects: 10
Study: 7948796

Group type: EXPERIMENTAL
Intervention: Amrinone (2 mg/kg bolus during CPB)
Number of subjects: 0
Study: 3358596

Group type: EXPERIMENTAL
Intervention: Intraocular epinephrine irrigation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (without intraocular epinephrine irrigation)
Number of subjects: 28
Study: 31198594

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (600 μg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 200
Study: 28017787

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 80

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 80
Study: 25451336

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (SET) - 2 hospital-based sessions and 1 home-based session per week for 12 weeks after PTA.
Number of subjects: 50

Group type: COMPARATOR
Intervention: PTA alone (Control group) - no additional follow-up regarding exercise.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (SET and Control)
Number of subjects: 50
Study: 24564041

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy plus medications (analgesics, nonsteroidal anti-inflammatory - diclofenac sodium)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard medications (analgesics, nonsteroidal anti-inflammatory - diclofenac sodium)
Number of subjects: 16
Study: 22247928

Group type: EXPERIMENTAL
Intervention: Topical 1% lidocaine cream
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 59
Study: 18936474

Group type: EXPERIMENTAL
Intervention: Vandetanib with paclitaxel and carboplatin (VPC)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin (PC)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Vandetanib monotherapy
Number of subjects: 181
Study: 16476120

Group type: EXPERIMENTAL
Intervention: Clarithromycin (CAM) for 3 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Supportive therapies only (Control)
Number of subjects: 34
Study: 12897047

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg/day of Zn as Zn gluconate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10650326

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9433655

Group type: EXPERIMENTAL
Intervention: grepafloxacin 600 mg once daily for 10 days with theophylline
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: grepafloxacin 600 mg once daily for 14 days with warfarin
Number of subjects: 16

Group type: COMPARATOR
Intervention: warfarin
Number of subjects: 16
Study: 8431336

Group type: EXPERIMENTAL
Intervention: Free clear fluids intake until premedication (mean 388 ml in 6 h before surgery)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (fasted for 6 h)
Number of subjects: 100
Study: 3315603

Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC) 30 units
Number of subjects: 87

Group type: COMPARATOR
Intervention: Heparin treatment
Number of subjects: 87
Study: 31744865

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy
Number of subjects: 2167
Study: 29080119

Group type: EXPERIMENTAL
Intervention: LDL apheresis
Number of subjects: 35
Study: 24619763

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 70 mg/week (n=41)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Raloxifene (RAL) 60 mg/d (n=37)
Number of subjects: 125

Group type: COMPARATOR
Intervention: No additional medication (n=47)
Number of subjects: 125
Study: 22450724

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.02 mg/mL)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Alfentanil 1 (0.04 mg/mL)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Alfentanil 2 (0.08 mg/mL)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 81
Study: 20707886

Group type: EXPERIMENTAL
Intervention: Robotic wheelchair trainer with haptic guidance
Number of subjects: 23

Group type: COMPARATOR
Intervention: Training without guidance
Number of subjects: 23
Study: 18208877

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 20 mg PO
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: IV methylprednisolone (IVMP) 1,000 mg/day for three days every other month
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a (IM IFNbeta-1a) 30 mcg IM weekly
Number of subjects: 313
Study: 16436547

Group type: EXPERIMENTAL
Intervention: Atomoxetine (maximum dose 1.8 mg/kg/day; n = 102)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo (n = 52)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 12472392

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation (CRT) followed by surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pathologic CR
Number of subjects: 0
Study: 9429680

Group type: EXPERIMENTAL
Intervention: Structured communication program (discussion with a nurse, informational pamphlet, daily telephone call)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Structured communication program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no structured communication program)
Number of subjects: 30
Study: 7813254

Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass with a 3:1 ratio
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass with a 1:3 ratio
Number of subjects: 36

Group type: COMPARATOR
Intervention: Unoperated obese patients
Number of subjects: 36
Study: 2757885

Group type: EXPERIMENTAL
Intervention: Inhaled NAAGA (60 mg thrice daily for 1 week)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 12
Study: 180199

Group type: EXPERIMENTAL
Intervention: 10 mg of adenine arabinoside/kg per day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 15 mg of adenine arabinoside/kg per day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 20 mg of adenine arabinoside/kg per day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 30 mg of adenine arabinoside/kg per day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 7305144

Group type: EXPERIMENTAL
Intervention: Routine electrocardiogram and serum creatine phosphokinase tests
Number of subjects: 176

Group type: COMPARATOR
Intervention: No diagnostic tests withheld
Number of subjects: 176
Study: 31697972

Group type: EXPERIMENTAL
Intervention: MSDC-0602K 62.5 mg
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: MSDC-0602K 125 mg
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: MSDC-0602K 250 mg
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: MSDC-0602K (all doses)
Number of subjects: 392
Study: 31783602

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU loading dose of cholecalciferol followed by 4000 IU daily for 16 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (matching placebo for 16 weeks)
Number of subjects: 26
Study: 30286855

Group type: EXPERIMENTAL
Intervention: Dual-therapy COMBO stent
Number of subjects: 3614
Study: 26228576

Group type: EXPERIMENTAL
Intervention: New chewable benazepril hydrochloride tablet (0.5 mg/kg p.o.)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Branded formulation (Fortekor®)
Number of subjects: 22
Study: 24428236

Group type: EXPERIMENTAL
Intervention: Alcohol intervention with a 45% reduction in unhealthy alcohol consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unhealthy alcohol consumption behaviors
Number of subjects: 0
Study: 22065305

Group type: EXPERIMENTAL
Intervention: 3 mg of norgestomet implant for 9 days with 500 IU PMSG at implant removal
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 3 mg of norgestomet implant for 9 days without PMSG
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group without hormonal treatment
Number of subjects: 80
Study: 19713152

Group type: EXPERIMENTAL
Intervention: AVI-4658 (0.09 mg in 900 microL saline)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: AVI-4658 (0.9 mg in 900 microL saline)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study: 17767200

Group type: EXPERIMENTAL
Intervention: 0.4% Dexamethasone sodium phosphate phonophoresis (PH)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.4% Dexamethasone sodium phosphate iontophoresis (ION)
Number of subjects: 50
Study: 15231012

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day and 5 mg/day
Number of subjects: 1099

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Alendronate (combined 5 mg and 10 mg groups)
Number of subjects: 1099

Group type: COMPARATOR
Intervention: Discontinuation of alendronate
Number of subjects: 1099
Study: 12032117

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 9836078

Group type: COMPARATOR
Intervention: Bone resorption in IBD patients
Number of subjects: 149

Group type: COMPARATOR
Intervention: Bone formation in IBD patients
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Prevalence of osteopenia and osteoporosis in IBD patients
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Bone metabolism imbalance in IBD patients
Number of subjects: 149
Study: 7926142

Group type: EXPERIMENTAL
Intervention: Saliva P measurements
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Plasma P measurements
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Single plasma P concentration (8:00 A.M.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Plasma pulse frequency, mean pulse interval, pulse width, pulse amplitude, and 24-hour mean P level
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Repeated saliva P samples
Number of subjects: 21
Study: 2591258

Group type: EXPERIMENTAL
Intervention: PolyI:C
Number of subjects: 90

Group type: COMPARATOR
Intervention: Inosine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Prednisone withdrawal followed by PolyI:C
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 1098888

Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.3 mg for seven days)
Number of subjects: 30
Study: 30085176

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (25(OH)D < 20 ng/mL or 50 nmol/L) in PPCOS II
Number of subjects: 1254

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency in pregnant subjects from both studies
Number of subjects: 1254

Group type: COMPARATOR
Intervention: Vitamin D deficiency in AMIGOS
Number of subjects: 1254
Study: 28040368

Group type: EXPERIMENTAL
Intervention: Internet-based information and self-help program with therapist contact
Number of subjects: 62

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 62
Study: 25534913

Group type: EXPERIMENTAL
Intervention: IFN-β
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 0
Study: 21950455

Group type: EXPERIMENTAL
Intervention: Validation from a third party
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Minimization of the transgression
Number of subjects: 2
Study: 21606192

Group type: EXPERIMENTAL
Intervention: DHEA 50 mg for 6 months
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 20050483

Group type: EXPERIMENTAL
Intervention: Reading handover (written communication between nurses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional oral handover
Number of subjects: 0
Study: 16948972

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg twice a day) and Vitamin E (400 IU per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no vitamin therapy)
Number of subjects: 40
Study: 15277403

Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: metformin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: both treatments
Number of subjects: 20
Study: 11783684

Group type: EXPERIMENTAL
Intervention: Continuous electronic fetal monitoring (EFM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent auscultation (IA)
Number of subjects: 0
Study: 9435196

Group type: EXPERIMENTAL
Intervention: Lisofylline (LSF) at doses of 1, 2, or 3 mg/kg every 24 hr for 3 days by 10 min intravenous infusion
Number of subjects: 12
Study: 8010459

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.4 mg and indomethacin 50 mg (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Buprenorphine 0.4 mg (Group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Indomethacin 50 mg (Group C)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No drug (Group D)
Number of subjects: 80
Study: 2776288

Group type: EXPERIMENTAL
Intervention: Menicon SF‐P rigid gas permeable (RGP) contact lenses
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Menicon EX rigid gas permeable (RGP) contact lenses
Number of subjects: 25
Study: 799980

Group type: EXPERIMENTAL
Intervention: Isoetharine ('Numotac') 10 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Isoetharine ('Numotac') 20 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Isoetharine ('Numotac')
Number of subjects: 39
Study: 30730043

Group type: EXPERIMENTAL
Intervention: Psychoeducational HIV/STI prevention intervention
Number of subjects: 108
Study: 27789452

Group type: EXPERIMENTAL
Intervention: Arterial spin-labeling/SWI
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional MR imaging
Number of subjects: 92
Study: 24444862

Group type: EXPERIMENTAL
Intervention: Auditory training
Number of subjects: 86

Group type: COMPARATOR
Intervention: Commercial computer games (Control)
Number of subjects: 86
Study: 25632575

Group type: COMPARATOR
Intervention: Medication (Aspirin and Panax Notoginseng Saponins)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 160

Group type: COMPARATOR
Intervention: Tongxinluo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Acupuncture + Tongxinluo
Number of subjects: 160
Study: 21730216

Group type: COMPARATOR
Intervention: Soy protein intake (median of 30 g/d)
Number of subjects: 43
Study: 19389902

Group type: EXPERIMENTAL
Intervention: Laser surgery for TTTS with cervical length >2.5 cm
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Laser surgery for TTTS with cervical length 2 to 2.5 cm
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Laser surgery for TTTS with cervical length 0.5 to 1.9 cm
Number of subjects: 99
Study: 17341994

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg, titrated to 40 mg at week 4, remained at 40 mg at week 8 and 12
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan potassium 50 mg, titrated to 50 mg twice daily at week 8
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg, titrated to 320 mg at week 8
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15231078

Group type: EXPERIMENTAL
Intervention: Iron administered once a week (60 mg as 300-mg ferrous sulfate tablets)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Iron administered twice a week (60 mg as 300-mg ferrous sulfate tablets)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Iron administered once a day (60 mg as 300-mg ferrous sulfate tablets)
Number of subjects: 150
Study: 11727882

Group type: EXPERIMENTAL
Intervention: Multidimensional family therapy (MDFT)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Adolescent group therapy (AGT)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Multifamily educational intervention (MEI)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: MDFT
Number of subjects: 182
Study: 9257209

Group type: EXPERIMENTAL
Intervention: Donor plasma transfusion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Albumin 5% (Control)
Number of subjects: 16
Study: 8506786

Group type: EXPERIMENTAL
Intervention: Maintenance newsletters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone hotline
Number of subjects: 0
Study: 3326115

Group type: EXPERIMENTAL
Intervention: Zopiclone 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zopiclone 2.5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Zopiclone (various doses)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (placebo not specified)
Number of subjects: 10
Study: 30414699

Group type: EXPERIMENTAL
Intervention: Retrieval practice with sham tDCS
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Retrieval practice with active anodal tDCS
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Retrieval practice with active cathodal tDCS
Number of subjects: 150

Group type: COMPARATOR
Intervention: Study practice with sham tDCS
Number of subjects: 150

Group type: COMPARATOR
Intervention: Study practice with active anodal tDCS
Number of subjects: 150

Group type: COMPARATOR
Intervention: Study practice with active cathodal tDCS
Number of subjects: 150
Study: 26833304

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study: 25527295

Group type: EXPERIMENTAL
Intervention: Fixed-combination bimatoprost/timolol (bim/tim)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Fixed-combination dorzolamide/brimonidine/timolol (dorz/brim/tim)
Number of subjects: 78
Study: 22308289

Group type: EXPERIMENTAL
Intervention: G-CSF-mobilized peripheral blood mononuclear cells (G-PBMCs)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Bone marrow
Number of subjects: 172
Study: 20376496

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg before surgery and repeated after 12 hours
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 99
Study: 18693743

Group type: EXPERIMENTAL
Intervention: Acai pulp
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acai juice
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Applesauce
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-antioxidant beverage
Number of subjects: 12